DOAC Therapy Reduced Serious Events in a Long-Contested Atrial Fibrillation Group
Intermediate-risk atrial fibrillation has long sat in a therapeutic gray zone. High-risk patients are routinely offered anticoagulation because clot prevention clearly outweighs bleeding concerns, but people with only modest stroke risk have been harder to place on the treatment map. The SINGLE-AF trial now adds randomized evidence to that debate, showing that newer oral anticoagulants lowered serious cardiovascular events without a measurable rise in major bleeding.
The trial’s message is clinically direct. Among 1,803 patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulants cut the primary composite endpoint from 1.5% to 0.5% over 24 months. The reduction was driven mainly by fewer ischemic strokes, the outcome clinicians worry about most when anticoagulation is withheld.
A Population That Has Been Hard to Treat With Confidence
Atrial fibrillation promotes blood stasis in the atria, platelet activation, and thrombus formation, which can then embolize to the brain or systemic circulation. When the stroke risk is clearly high, anticoagulation is easy to justify because the biological mechanism and the event reduction line up cleanly. The challenge has been the intermediate-risk subgroup, where the absolute event rate is lower and the balance between benefit and harm becomes harder to judge at the bedside.
Guidelines have reflected that uncertainty. For patients at intermediate stroke risk, oral anticoagulation has been something to consider rather than a blanket recommendation. Earlier observational studies, especially those involving vitamin K antagonists, produced conflicting results and did not settle the question in a way that could confidently guide routine practice.
Professor Boyoung Joung of Yonsei University framed the need for randomized evidence plainly: observational data had remained inconsistent in this group, and SINGLE-AF was designed to test whether newer direct oral anticoagulants truly help patients with atrial fibrillation at intermediate risk of stroke.
Trial Design Focused on Common Bedside Decisions
SINGLE-AF was an open-label study conducted at 18 medical centers in South Korea. The enrolled population included patients with atrial fibrillation whose stroke risk was defined as a CHA2DS2-VASc score of 1 in men or 2 in women. Participants were randomized 1:1 to receive either no anticoagulation or treatment with a direct oral anticoagulant, specifically apixaban 5 mg twice daily or rivaroxaban 20 mg once daily.
Those doses reflect familiar real-world prescribing patterns, which matters because the trial was not testing an exotic regimen or a niche drug strategy. It was asking a practical question: in patients who fall between obvious treatment and obvious omission, does a modern anticoagulant prevent enough harm to justify routine use?
The answer moved in favor of treatment.
Stroke Prevention Drove the Benefit Signal
After 24 months, the primary endpoint fell sharply in the anticoagulated group. Serious events occurred in 0.5% of patients receiving DOAC therapy and in 1.5% of those receiving no anticoagulation, yielding a hazard ratio of 0.31 with a 95% confidence interval of 0.10 to 0.94 and a p value of 0.028. The endpoint combined stroke, systemic embolism, major bleeding, and cardiovascular death.
The most important biological and clinical signal came from ischemic stroke. Only 0.1% of patients taking a DOAC experienced ischemic stroke, compared with 1.1% of patients who did not receive anticoagulation. In a disorder where embolic stroke can be sudden, disabling, and irreversible, even small absolute differences matter because they translate into avoided neurologic injury, loss of independence, and downstream rehabilitation needs.
The bleeding profile did not erode the benefit. Major bleeding occurred in 0.3% of patients receiving DOAC therapy and 0.5% of those assigned to no anticoagulation. In practical terms, the feared trade-off did not materialize in this trial.
Why the Result Fits the Pharmacology
Direct oral anticoagulants inhibit key steps in the coagulation cascade and reduce the formation of fibrin-rich thrombi that can form in the fibrillating atrium. Unlike older vitamin K antagonists, DOACs have more predictable pharmacokinetics and generally simpler dosing, which has improved their use in contemporary cardiovascular care. In a population with enough thromboembolic risk to matter but not so much that every clinician has already committed to treatment, that pharmacologic predictability becomes especially relevant.
The trial also helps explain why the event curves favored treatment despite the lower-risk profile of the cohort. Intermediate-risk atrial fibrillation still generates embolic risk, and when anticoagulation suppresses clot formation early enough, the downstream consequence is fewer ischemic strokes. The mechanism is straightforward; the clinical hesitation has been the missing randomized proof.
What the Trial Does and Does Not Resolve
SINGLE-AF provides the first randomized evidence supporting DOAC use in atrial fibrillation patients at intermediate stroke risk. It does not erase every uncertainty around anticoagulation decisions. The trial was open-label, conducted in South Korea, and used a specific intermediate-risk definition based on CHA2DS2-VASc scoring. Those features should shape how broadly clinicians extrapolate the findings.
Even so, the core result is hard to ignore. A treatment once reserved for clearer-cut risk profiles produced fewer serious cardiovascular events, chiefly by reducing ischemic stroke, and it did so without a visible increase in major bleeding. For patients and clinicians making anticoagulation decisions in the intermediate-risk zone, that is the kind of signal that can move practice.
Professor Joung said the trial’s data may inform future guideline recommendations and reimbursement policies. The next step is not to ask whether anticoagulation works in high-risk atrial fibrillation; that question is already settled. The remaining issue is how quickly guideline writers will incorporate randomized evidence into the more ambiguous middle ground, where treatment decisions have been most difficult to justify with confidence.